- consolidation reports
J Clin Oncol. 2008 Nov: Phase III
trial of consolidation therapy with yttrium-90-ibritumomab
tiuxetan compared with no additional therapy after first
remission in advanced follicular lymphoma.
Consolidation of first remission with (90)Y-ibritumomab tiuxetan
in advanced-stage follicular lymphoma is highly effective with
no unexpected toxicities, prolonging PFS by 2 years and
resulting in high PR-to-CR conversion rates regardless of type
of first-line induction treatment.
Ann Oncol. 2012 Feb: A phase
II trial of short course fludarabine, mitoxantrone, rituximab
followed by 90Y-ibritumomab tiuxetan in untreated
intermediate/high-risk follicular lymphoma
Results: All the 55 patients
received four induction cycles with an overall response rate of
96% (38 complete responses [CR] and 15 PR). Fifty-one patients
(38 in CR and 13 in PR) received 90Y-IT. By the end of the
treatment, 49/55 patients achieved a CR. With a median follow-up
of 21 months, the estimated 3-year PFS was 81% and the 3-year OS
Conclusions: This study has established feasibility,
tolerability, and efficacy of a regimen composed by short FMR
induction with 90Y-IT consolidation in untreated
intermediate/high-risk follicular NHL patients.